Results 221 to 230 of about 116,563 (269)
Some of the next articles are maybe not open access.

Targeting KRAS in cancer

Nature Medicine
RAS family variants-most of which involve KRAS-are the most commonly occurring hotspot mutations in human cancers and are associated with a poor prognosis. For almost four decades, KRAS has been considered undruggable, in part due to its structure, which lacks small-molecule binding sites.
Anupriya Singhal   +2 more
openaire   +2 more sources

KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma

Molecular Cancer Therapeutics
Abstract Pancreatic ductal adenocarcinoma (PDAC) is associated with significant morbidity and mortality and is projected to be the second leading cause of cancer-related deaths by 2030. Mutations in KRAS are found in the vast majority of PDAC cases and plays an important role in the development of the disease.
Minh T. Than   +3 more
openaire   +2 more sources

KRAS inhibitors, approved

Nature Cancer, 2021
Rafael Rosell   +3 more
openaire   +2 more sources

KRAS

2020
Daniela Furlan, Nora Sahnane
openaire   +1 more source

The Kra Canal

1975
From the solid body of Asia a narrow peninsula runs south, ending in the island of Singapore and separating the Andaman Sea from the Gulf of Thailand and the South China Sea. In its northern end Burma and Thailand share the peninsula, Thailand at the eastern side.
openaire   +1 more source

Targeting the MAPK Pathway in KRAS-Driven Tumors

Cancer Cell, 2020
Matthias Drosten, Mariano Barbacid
exaly  

Redefining KRAS activation

Nature Reviews Clinical Oncology, 2018
openaire   +2 more sources

Home - About - Disclaimer - Privacy